Ageing, Cellular Senescence and Neurodegenerative Disease
Open accessThe DOI matches its Crossref record; 374 of the 385 references it cites were found in a registry or an index; 63 of the 277 sources its claims cite were checked for support.
Abstract
Ageing is a major risk factor for developing many neurodegenerative diseases. Cellular senescence is a homeostatic biological process that has a key role in driving ageing. There is evidence that senescent cells accumulate in the nervous system with ageing and neurodegenerative disease and may predispose a person to the appearance of a neurodegenerative condition or may aggravate its course. Research into senescence has long been hindered by its variable and cell-type specific features and the lack of a universal marker to unequivocally detect senescent cells. Recent advances in senescence markers and genetically modified animal models have boosted our knowledge on the role of cellular senescence in ageing and age-related disease. The aim now is to fully elucidate its role in neurodegeneration in order to efficiently and safely exploit cellular senescence as a therapeutic target. Here, we review evidence of cellular senescence in neurons and glial cells and we discuss its putative role in Alzheimer’s disease, Parkinson’s disease and multiple sclerosis and we provide, for the first time, evidence of senescence in neurons and glia in multiple sclerosis, using the novel GL13 lipofuscin stain as a marker of cellular senescence.
Overview
CoChat Summary
TL;DR
This review argues that cellular senescence contributes to ageing and neurodegenerative disease, with senescent cells accumulating in the nervous system and potentially influencing disease susceptibility, onset, and progression. It also reports novel GL13 lipofuscin evidence of senescent glia and neurons in secondary progressive multiple sclerosis lesions.
Key findings
- Cellular senescence is a homeostatic response triggered by irreparable DNA damage; senescent cells increase with ageing and are implicated in Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The review states a primary causative role in neurodegeneration is unlikely, but senescence may contribute to susceptibility, age at presentation, and rate of progression.
- Senescence-like features are reported across CNS cell types, including astrocytes, microglia, oligodendrocytes, oligodendrocyte progenitor cells, neurons, and neural stem cells. In aged mice, about 20–80% of mature neurons exhibit a senescence-like phenotype; oligodendrocyte progenitor cells constitute approximately 3–10% of glial cells; brain volume loss may amount to up to 0.4% annually.
- Disease-specific evidence includes elevated p16INK4a mRNA in PD brain, increased SA-β-gal in CSF from PD patients, and elevated SASP-related cytokines in AD and PD. However, a meta-analysis showed no difference in telomere length between PD patients and age-matched controls, and AD telomere findings remain inconclusive.
- Novel MS findings: GL13 lipofuscin histochemistry detected lipofuscin+ glial cells in acute active and chronic active demyelinated white matter lesions from SP-MS cases, sparse cells in chronic inactive lesions, none in normal appearing white matter, and granular lipofuscin deposits in numerous neurons in subpial demyelinated cortical lesions and normal appearing cortex.
Methods
- Narrative review of cellular senescence in ageing and neurodegeneration, focusing on Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
- For the new MS evidence, the authors used GL13 (SenTraGor) lipofuscin histochemistry as a senescence marker on MS white matter lesions, normal appearing white matter, and cortical lesions; they also cite cuprizone-induced demyelination model data with correlation analysis between senescent glial cell number and demyelination/motor performance.
- No systematic review, meta-analysis, or primary sample size/statistical methods are stated for the MS histochemistry.
Limitations
- Stated: evidence connecting cellular senescence with mechanisms of neurodegeneration remains indirect and further investigation is required.
- Stated: the MS findings merit further quantitative investigation to differentiate ageing effects from MS and to associate senescence extent with other pathological and clinical parameters.
- Stated: no universal specific senescence marker exists and no consensus on optimal marker combination; senescence features are variable and cell-type specific. Evident: as a narrative review, it does not provide systematic search/quality assessment, and the primary MS histochemistry sample details are not reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Lipofuscin accumulation as a marker of cellular senescence in multiple sclerosis lesions. Demyelinated lesions were identified with myelin basic protein (MBP) immunohistochemistry and were staged according to Trapp et al. (1998) [287] as acute active, chronic active or chronic inactive using human leukocyte antigen-DR isotype (HLA-DR) immunohistochemistry on serial sections from paraffin embedded postmortem tissue blocks. Lipofuscin was detected with the GL13 hybrid histochemistry-immunohistochemistry method [58]. Acute active demyelinated white matter lesion with MBP staining showing ongoing perivascular demyelination in subcortical white matter from the parietal lobe of a 73-year-old secondary progressive multiple sclerosis (SP-MS) patient (MS51) (A(i)). Infiltration with HLA-DR+ cells with macrophage morphology throughout the demyelinated parenchyma (HLA DR immunohistochemistry) (A(ii)). Perivascular infiltration with CD8+ lymphocytes (CD8 immunohistochemistry) (A(iii)). GL13 staining in acute active lesions showed lipofuscin+ cells. Although many of them were perivascularly localized, some were not, suggesting that at least some of them maybe glial cells rather than inflammatory cells (A(iv)). Chronic actively demyelinating perivenentricular white matter lesion with a fully demyelinated lesion center (lack of MBP immunoreactivity) from a 74-year-old female MS patient (MS265) (B(i)). Typically, HLA-DR immunohistochemistry of serial sections exhibited a border infiltrated by numerous macrophages whereas the lesion centre is infiltrated by ramified microglia (B(ii)). Few CD8+ lymphocytes are present perivascularly (CD8 immunohistochemistry) (B(iii)). Lipofuscin+ cells with granular staining were found in the macrophage infiltrated lesion border (B(iv)). Chronic inactive subcortical white matter demyelinated lesion (lack of MBP immunoreactivity with a well demarcated border) from the left parietal lobe of a 71-year-old female SP-MS patient (MS33) (C(i)). Ramified microglial morphology throughout the demyelinated lesion area and lesion border (HLA-DR immunohistochemistry) typical of a chronic inactive lesion (C(ii)). Decreased axonal density in the demyelinated lesion seen with 200 KDa neurofilament immunohistochemistry (C(iii)). Numerous parenchymal lipofuscin+ cells in the demyelinated white matter. Lack of HLA-DR+ macrophages from the chronic demyelinated lesion suggests that the lipofuscin+ cells are glial (C(iv)). Subpial cortical demyelination (lack of MBP immunoreactivity extending from the pial surface into the deeper cortical layers from the parietal cortex of a 71-year-old female SP-MS patient (MS33) (D(i)). HLA-DR+ ramified microglia in the demyelinated cortical lesion (D(ii)) and few CD8+ lymphocytes infiltrating the adjacent pia matter (D(iii)). Lipofuscin+ cells mostly with neuronal morphology (inset) throughout the demyelinated cortex (D(iv)). Normal appearing cortex with intact appearing cortical myelin (MBP immunohistochemistry) from the left parietal lobe of a 71-year-old female SP-MS patient (MS33) (E(i)), HLA-DR immunoreactivity revealing quiescent ramified microglia (E(ii)) and normal-appearing axonal staining with 200 kDa neurofilament immunohistochemistry on a serial section (E(iii)). GL13 staining showed numerous lipofuscin+ cells mostly with neuronal morphology (E(iv)). Scale bars represent 500 μm (A(i),A(ii),B(i),B(ii),C(i),C(ii),C(iii),D(i),D(ii),E(i),E(ii)), 50 μm (D(iii),E(iii)) or 25 μm (A(iii),A(iv), B(iii), B(iv), C(iv), D(iv), E(iv)).](https://figures.cochat.ai/paper-figures/6bbbad0f51864a21a639dec131aee479/ageing-cellular-senescence-and-neurodegenerative-disease-figure-1.jpg)
Verification
Claims the paper makes
34 Valid · 2 Not valid · 116 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Age is the strongest predictor for the transition from the relapsing phase of MS, which is primarily inflammatory to the secondary progressive phase of the disease, which is thought to be mainly neurodegenerative [10,11].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 1. Ageing and Neurodegeneration
What the sources say
- Not checked yetcites [10] Trapp B.D. Nave K.-A. Multiple Sclerosis: An Immune or Neurodegenerative Disorder? Annu. Rev. Neurosci. 2008 31 247 269 10.1146/annurev.neuro.30.051606.094313 18558855 source
- Partly supportedcites [11] Scalfari A. Neuhaus A. Daumer M. Ebers G.C. Muraro P.A. Age and disability accumulation in multiple sclerosis Neurology 2011 77 1246 1252 10.1212/WNL.0b013e318230a17d 21917763 PMC3179646 sourceExperimental — accuracy not yet measured
The Age at disease onset section reports that older age at relapsing-remitting onset increases the probability of conversion to secondary progressive MS. The Multiple analysis section finds an age effect independent of early relapse frequency, but does not establish age as the strongest predictor. Page numbers are not available in our copy. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Incidence of Parkinson’s disease (PD), the second most common age-related neurodegenerative condition also increases with age [8,9].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 1. Ageing and Neurodegeneration
What the sources say
- Not checked yetcites [8] Blin P. Dureau-Pournin C. Foubert-Samier A. Grolleau A. Corbillon E. Jové J. Lassalle R. Robinson P. Poutignat N. Droz-Perroteau C. Moore N. Parkinson’s disease incidence and prevalence assessment in France using the national healthcare insurance database Eur. J. Neurol. 2015 22 464 471 10.1111/ene.12592 25389031 source
- Supportedcites [9] Duncan G.W. Khoo T.K. Coleman S.Y. Brayne C. Yarnall A.J. O’Brien J.T. Barker R.A. Burn D.J. The incidence of Parkinson’s disease in the North-East of England Age Ageing 2014 43 257 263 10.1093/ageing/aft091 23880142 source
The Key points section (p. 1 of that block) states outright 'The incidence of PD increases with age', and the Discussion reports that incidence 'peaked in the eighth decade' with 68% of new diagnoses aged over 70, backed by the age- and sex-specific crude rates in Table 2 (rising from 0.4 per 100 000 at 0-39 to 110.0 at 70-79). The Introduction also supports the framing that PD is 'the second most common neurodegenerative disorder after Alzheimer's disease'. The only caveat is the drop-off after 80, which the authors themselves flag as possibly reflecting under-ascertainment rather than a true decline. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another key feature of cellular senescence is the senescence-associated secretory phenotype (SASP), which is dependent on p38MAPK (p38 mitogen-activated protein kinases), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), cGAS(cyclic GMP-AMP synthase)/STING(stimulator of IFN genes), NOTCH and mTORmammalian target of rapamycin) signalling [38,39,40,41,42].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 3. The Senescence Phenotype
What the sources say
- Partly supportedcites [38] Baker D.J. Wijshake T. Tchkonia T. LeBrasseur N.K. Childs B.G. van de Sluis B. Kirkland J.L. van Deursen J.M. Clearance of p16Ink4a -positive senescent cells delays ageing- associated disorders Nature 2012 479 232 236 10.1038/nature10600 22048312 PMC3468323 sourceExperimental — accuracy not yet measured
The paper’s concluding discussion describes the senescence-associated secretory phenotype (SASP) as enabling secretion of growth factors, cytokines and proteases. It does not address whether SASP depends on p38MAPK, NF-κB, cGAS/STING, NOTCH or mTOR signalling (pages unavailable in our copy). (LLM, conf=0.85)
- Not checked yetcites [39] Krenning L. Feringa F.M. Shaltiel I.A. VandenBerg J. Medema R.H. Transient activation of p53 in G2 phase is sufficient to induce senescence Mol. Cell 2014 55 59 72 10.1016/j.molcel.2014.05.007 24910099 source
- Could not verifycites [40] Stein G.H. Drullinger L.F. Soulard A. Dulić V. Differential Roles for Cyclin-Dependent Kinase Inhibitors p21 and p16 in the Mechanisms of Senescence and Differentiation in Human Fibroblasts Mol. Cell. Biol. 1999 19 2109 2117 10.1128/MCB.19.3.2109 10022898 PMC84004 sourceExperimental — accuracy not yet measured
The Results and Discussion describe altered expression of extracellular-matrix-related genes in senescent fibroblasts, but do not address whether the senescence-associated secretory phenotype depends on the listed signalling pathways. Searches for SASP and for p38MAPK, NF-κB, cGAS/STING, NOTCH and mTOR found no passage establishing those dependencies. (LLM, conf=0.76)
- Could not verifycites [41] Sharma V. Gilhotra R. Dhingra D. Gilhotra N. Possible underlying influence of p38MAPK and NF-κB in the diminished anti-anxiety effect of diazepam in stressed mice J. Pharmacol. Sci. 2011 116 257 263 10.1254/jphs.11026FP 21720097 sourceExperimental — accuracy not yet measured
The Discussion addresses a possible p38MAPK–NF-κB relationship in immobilization-stress-induced anxiety in mice, not in cellular senescence. Searches for SASP, cellular senescence, cGAS/STING, NOTCH, and mTOR found no passage linking these pathways to the secretory phenotype. Page numbers were not available in our copy. (LLM, conf=0.78)
- Partly supportedcites [42] Yang H. Wang H. Ren J. Chen Q. Chen Z.J. cGAS is essential for cellular senescence Proc. Natl. Acad. Sci. USA 2017 114 E4612 E4620 10.1073/pnas.1705499114 28533362 PMC5468617 sourceExperimental — accuracy not yet measured
The Results report that cGAS deletion prevented induction of SASP genes after etoposide treatment, and the introductory text describes STING as a downstream component of cGAS signalling. But the paper does not establish that SASP depends on STING; the Discussion also raises STING-independent roles for cGAS. This citation supports the cGAS portion of the cited signalling claim, not its asserted STING dependence. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Altered mitochondrial function appears essential in mediating the senescence phenotype.”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 3. The Senescence Phenotype
What the sources say
- Partly supportedcites [60] Correia-Melo C. Marques F.D. Anderson R. Hewitt G. Hewitt R. Cole J. Carroll B.M. Miwa S. Birch J. Merz A. Mitochondria are required for pro-ageing features of the senescent phenotype EMBO J. 2016 35 724 742 10.15252/embj.201592862 26848154 PMC4818766 sourceExperimental — accuracy not yet measured
The Results report that mitochondrial depletion reduced multiple senescence markers and pro-inflammatory signals. The Discussion describes mitochondria as key to major ageing-promoting features, but says they are less important for proliferation arrest, which persisted after depletion. Thus the paper supports their role in major features, not their being essential to the entire senescence phenotype. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ageing brain has higher background levels of low-grade inflammation primarily in the form of dystrophic microglia and increased levels pro-inflammatory cytokines and other mediators, a state known as inflammaging [100,101,102].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 5. Cellular Senescence and Its Putative Role in Neurodegeneration
What the sources say
- Not checked yetcites [100] Streit W.J. Sammons N.W. Kuhns A.J. Sparks D.L. Dystrophic Microglia in the Aging Human Brain Glia 2004 45 208 212 10.1002/glia.10319 14730714 source
- Not checked yetcites [101] Rawji K.S. Mishra M.K. Michaels N.J. Rivest S. Stys P.K. Yong V.W. Immunosenescence of microglia and macrophages: Impact on the ageing central nervous system Brain 2016 139 653 661 10.1093/brain/awv395 26912633 PMC5839598 source
- Partly supportedcites [102] Olivieri F. Prattichizzo F. Grillari J. Balistreri C.R. Cellular Senescence and Inflammaging in Age-Related Diseases Med. Inflamm. 2018 2018 1 6 10.1155/2018/9076485 29849499 PMC5932453 sourceExperimental — accuracy not yet measured
In the main text (page unavailable), the paper defines inflammaging as chronic, systemic, low-grade inflammation and describes secretion of pro-inflammatory mediators. It also mentions a link between inflammaging and neurodegenerative diseases, but does not describe higher background inflammation specifically in the ageing brain or identify dystrophic microglia as its primary form. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
122 more claims · 25 with their cited sources checked
Create a free account to see all 185 claims and to verify the 214 references still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 49
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Age‐related alterations in the brain microenvironment gradually led to increased BBB permeability and leakiness, neuronal degeneration, production of reactive oxygen species (ROS) and inflammation. 54 , 55 , 56”
From Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review (2023) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The senescence stress response allows damaged cells to survive by upregulating senescent cell anti-apoptotic pathways (SCAPs)10 and causes inflammation through their senescence-associated secretory phenotype (SASP)11,12.”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“TMAO is an amine oxide product of the bacterial metabolism that has been implicated in oxidative stress enhancement, BBB disruption, mitochondria dysfunction, brain aging and neurodegeneration [105,106,107]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“Through dysregulation of p38 mitogen-activated protein kinases (p38MAPK), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), NOTCH, and mammalian target of rapamycin (mTOR) signaling, senescent cells can develop a senescence-associated secretory phenotype (SASP) (22, 23).”
From Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial (2022) · cites this paper as [22]
In the citing paper
“Senescence of the central nervous system (CNS) drives many neurodegenerative diseases [55], including Alzheimer’s disease (AD), Parkinson’s disease (PD) and other types of dementia (Table 1).”
From Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases (2020) · cites this paper as [55]
Citations
Cites
1 retracted
Zheng, J., Son, D. J., Gu, S. M., Woo, J. R., Ham, Y. W., Lee, H. P., Kim, W. J., Jung, J. K., & Hong, J. T. (2016) · Scientific Reports · doi:10.1038/srep26357 · Cited by 92
RetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 3×
“Genomic instability, telomere attrition, loss of proteostasis, dysregulated nutrient sensing, mitochondrial dysfunction, stem cell exhaustion, altered cellular communication and excessive cellular senescence have all been recognized as hallmarks of ageing [14].”
BackgroundThe serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1×
“According to the original observations by Hayflick and Moorhead (1961), when cultures of normal human fibroblasts were passaged serially they underwent stable cell cycle arrest that was accompanied by stereotypical phenotypic changes [21].”
MethodA biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 1×
“0, which is measured using in situ staining with the chromogenic substrate X-gal [senescence-associated β-galactosidase activity (SA-β-gal)] is today the most widely used biomarker for detecting senescent cells [79,87].”
MethodThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“Cognitive decline in AD is associated with the disseminated formation of extracellular amyloid plaques, intracellular neurofibrillary tangles comprising of hyperphosphorylated tau proteins, as well as neuronal and synaptic loss [183].”
BackgroundCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 1×
“The astrocyte is the most abundant cell type of the CNS with a prominent role in the complex functions of the healthy CNS, as well as in various pathologies [136].”
Background
Research works printed but not linked: 2
- Ay M. Charli A. Jin H. Anantharam V. Kanthasamy A. Kanthasamy A.G. Quercetin Nutraceuticals Gupta R.C. Academic Press Boston, MA, USA 2016 447 452
- Schnekenburger M. Diederich M. Nutritional Epigenetic Regulators in the Field of Cancer: New Avenues for Chemopreventive Approaches Epigenetic Cancer Therapy Gray S.G. Academic Press Boston, MA, USA 2015 393 425
Cited by
Items 201–300 of 442
Venkataraman, A., Kordic, I., Li, J., Zhang, N. Y., Bharadwaj, N. S., Fang, Z., Das, S., & Coskun, A. F. (2024) · npj Aging · doi:10.1038/s41514-024-00178-w · Cited by 23
Breast cancer type 1 and neurodegeneration: consequences of deficient DNA repair
Leung, E., & Hazrati, L. (2021) · Brain Communications · doi:10.1093/braincomms/fcab117 · Cited by 16
Wilkins, J. M., Gakh, O., Kabiraj, P., McCarthy, C. B., Tobin, W. O., Howe, C. L., & Lucchinetti, C. F. (2020) · Aging · doi:10.18632/aging.103612 · Cited by 13
Multiplatform Lipid Analysis of the Brain of Aging Mice by Mass Spectrometry
Panda, P., Ferreira, C. R., Cooper, B. R., Schaser, A. J., & Aryal, U. K. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00688 · Cited by 19
Parandavar, E., Shafizadeh, M., Ahmadian, S., & Javan, M. (2024) · Aging Cell · doi:10.1111/acel.14211 · Cited by 14
Liu, S., Dai, H., Wang, R., & Zhang, X. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104965 · Cited by 15
Duarte, L. F., Villalobos, V., Farías, M. A., Rangel-Ramírez, M. A., González-Madrid, E., Navarro, A. J., Carbone-Schellman, J., Domínguez, A., Álvarez, A., Riedel, C. A., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06486-x · Cited by 18
Amini, R., Moradi, S., Najafi, R., Mazdeh, M., & Taherkhani, A. (2024) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2024/6654606 · Cited by 17
Advances in Nanotherapy for Targeting Senescent Cells
Shi, Y., Zhang, Y., Zhang, Y., Yao, J., Guo, J., Xu, X., & Wang, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s469110 · Cited by 23
Bjerregaard, V. A., Schönewolf‐Greulich, B., Rasmussen, L. J., Desler, C., & Tümer, Z. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00163 · Cited by 14
Liu, Y., Kang, M., Wei, W., Hui, J., Gou, Y., Liu, C. Y., Zhou, R., Wang, B., Shi, P., Liu, H., et al. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100271 · Cited by 16
Pastore, D., Pacifici, F., Dave, K. R., Palmirotta, R., Bellia, A., Pasquantonio, G., Guadagni, F., Donadel, G., Daniele, N. D., Abete, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143544 · Cited by 13
Recent Advances in the Roles of MicroRNA and MicroRNA-Based Diagnosis in Neurodegenerative Diseases
Zhang, J., Chen, Z., Chen, H., Deng, Y., Li, S., & Jin, L. J. (2022) · Biosensors · doi:10.3390/bios12121074 · Cited by 13
Wang, J., Zheng, B., Wang, F., Wang, F., Wang, J., & Wang, J. (2021) · Human Cell · doi:10.1007/s13577-021-00611-2 · Cited by 13
Phytopharmaceuticals and Herbal Approaches to Target Neurodegenerative Disorders
Islam, A., Mishra, A., Ahsan, R., & Fareha, S. (2023) · Drug Research · doi:10.1055/a-2076-7939 · Cited by 15
Yang, S., Dong, Y., Liu, Y. S., Yan, X., Sun, G., Jia, G., Li, X., Liu, H., Su, H., & Li, Y. (2021) · Biogerontology · doi:10.1007/s10522-021-09937-8 · Cited by 13
Applications of nanodiamonds in the diagnosis and treatment of neurological diseases
Tang, G. F., Zhang, M. R., Liu, Q., Tian, X., & R., R. (2022) · Journal of Nanoparticle Research · doi:10.1007/s11051-022-05434-2 · Cited by 13
Wang, Z., Feng, W., Li, X., Yun, X., Wu, S., Du, L., & Wang, H. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103035 · Cited by 19
AP2A1 modulates cell states between senescence and rejuvenation
Chantachotikul, P., Liu, S., Furukawa, K. T., & Deguchi, S. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111616 · Cited by 17
Senescent Astrocytes: A New Player in Brain Aging and Cognitive Decline
Pessoa, B., Hayashide, L. D. S., Dias, G. R., Pontes, B., Pinto, R. S., & Diniz, L. P. (2026) · Brain Sciences · doi:10.3390/brainsci16010076 · Cited by 14
An in vitro senescence model of gingival epithelial cell induced by hydrogen peroxide treatment
Giri, S., Takada, A., Paudel, D., Yoshida, K., Furukawa, M., Kuramitsu, Y., Matsushita, K., Abiko, Y., & Furuichi, Y. (2021) · Odontology · doi:10.1007/s10266-021-00630-3 · Cited by 14
Cellular Senescence in Glial Cells: Implications for Multiple Sclerosis
Maupin, E. A., & Adams, K. L. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.16301 · Cited by 12
Zhu, F., Yin, S., Wang, Y., Zhong, Y., Ji, Q., & Wu, J. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s499406 · Cited by 11
Wu, W., Mi, Y., Meng, Q., Li, N., Li, W., Wang, P., & Hou, Y. (2024) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2024.09.001 · Cited by 19
He, Y., Lipa, K. E., Alexander, P. G., Clark, K. L., & Lin, H. (2022) · Biology · doi:10.3390/biology11070996 · Cited by 16
Circadian system and aging: where both times interact
Cobarro, C., Soares, L. I., Kutsenko, Y., & Tomás‐Loba, A. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1646794 · Cited by 16
Liu, Y., Song, S., Li, X., Wang, J., Bao, Y., Wang, X., Lian, L., Liu, X., & Ma, W. (2024) · Pharmaceuticals · doi:10.3390/ph17091231 · Cited by 13
El‐Kadi, R. A., Abdelkader, N. F., Zaki, H. F., & Kamel, A. S. E. D. (2024) · Drug Development Research · doi:10.1002/ddr.22157 · Cited by 10
The intersection between toxicology and aging research: A toxic aging coin perspective
Wise, J. P. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1014675 · Cited by 14
The putative contribution of cellular senescence to driving tauopathies
Karabag, D., Heneka, M. T., & Ising, C. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.006 · Cited by 11
Yang, Z.-J., Wang, Y., Zhao, S., Hu, N., Chen, D., & Ma, H. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1961822 · Cited by 13
Targeted Therapeutics Delivery by Exploiting Biophysical Properties of Senescent Cells
Low, J., Chan, B., & Tay, A. K. P. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107990 · Cited by 11
Supplementation with Queen Bee Larva Powder Extended the Longevity of Caenorhabditis elegans
Zhao, T., Wu, L., Fan, F., Yang, Y., & Xue, X. (2022) · Nutrients · doi:10.3390/nu14193976 · Cited by 11
Interrogating the regulatory epigenome of cellular senescence
Thanos, D.-F., Ntintas, O. A., Athanasiadis, E. I., Papaspyropoulos, A., Petty, R., & Gorgoulis, V. G. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05848-w · Cited by 12
Self-citationUnraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Fu, L., Yu, B., Zhang, Y., Cao, S., lv, B., Tian, Y., Chen, H., Yang, S., Hu, Y., Hua, J., et al. (2023) · Aging · doi:10.18632/aging.204804 · Cited by 15
Alzheimer’s Disease and Premature Ovarian Insufficiency
Vujović, S., Ivović, M., Tančić‐Gajić, M., Marina, L., Jovičić-Pavlović, S., Pavlović, N., & Erić-Jovičić, M. (2023) · Endocrines · doi:10.3390/endocrines4020020 · Cited by 11
Lee, S., Suh, Y. J., Lee, Y., Yang, S., Hong, D. G., Thirumalai, D., Chang, S., Chung, K. W., Jung, Y., Moon, H. R., et al. (2021) · Antioxidants · doi:10.3390/antiox10111855 · Cited by 12
N6-Methyladenosine Methylation of mRNA in Cell Senescence
Zhang, L., & Xia, J. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01168-2 · Cited by 10
Manavi, Z., Melchor, G. S., Bullard, M. R., Gross, P. S., Ray, S., Gaur, P., Baydyuk, M., & Huang, J. K. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03425-3 · Cited by 10
Factors influencing gait performance in older adults in a dual-task paradigm
Andrade-Lara, K. E., Linares, J. C. C., MONTILLA, J. A. P., & Román, P. Á. L. (2024) · GeroScience · doi:10.1007/s11357-023-01052-5 · Cited by 11
Targeting the microbiota-mitochondria crosstalk in neurodegeneration with senotherapeutics
Homolak, J. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.018 · Cited by 10
Kretschmer, J. R., Tkachenko, D. P., Kümpfel, T., Havla, J. B., Engels, D., Paul, F., Schindler, P., Bellmann–Strobl, J., Berthele, A., Giglhuber, K., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575613 · Cited by 14
Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders
Lui, A., Do, T., Alzayat, O., Yu, N., Phyu, S. M., Santuya, H. J., Liang, B., Kailash, V., Liu, D., Inslicht, S. S., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17040426 · Cited by 9
Pai, V., Singh, B. N., & Singh, A. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102753 · Cited by 8
Zhu, M., Ling, X., Zhou, S. Y., Meng, P., Chen, Q., Chen, S., Shen, K., Xie, C., Kong, Y., Wang, M., et al. (2022) · Kidney Diseases · doi:10.1159/000526139 · Cited by 9
Honey Ameliorate Negative Effects in Neurodegenerative Diseases: An Evidence-Based Review
Nordin, A., Saim, A. B., & Idrus, R. B. H. (2021) · Sains Malaysiana · doi:10.17576/jsm-2021-5003-20 · Cited by 8
Pereira, Z. S., da Silva, A. S., Melo, J. C. D. N., dos Santos, J. C., Sampaio, P. Y. S., Silva, R. J. D. S., Araújo, R. H. D. O., & Sampaio, R. A. C. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20146329 · Cited by 11
Villa‐Cedillo, S. A., Acosta-Espinoza, E. J., Soto‐Domínguez, A., Rodríguez‐Rocha, H., Montes-de-Oca-Saucedo, C. R., García‐García, A., Loera‐Arias, M. D. J., Ríos-Vazquez, C. S., Sánchez-Torres, G., Valdés, J., et al. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102494 · Cited by 11
Kumar, S., Malviya, R., Sridhar, S. B., Shareef, J., & Wadhwa, T. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100369 · Cited by 11
Excess iron accumulation mediated senescence in diabetic kidney injury
Cheng, X., Li, Y., Chen, L., Jiang, C., Peng, S., Yao, P., & Tang, Y. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23683 · Cited by 9
Wang, Y., Gong, Q., Pan, H., Wang, X., & Yan, C. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148687 · Cited by 8
Association between premature ovarian insufficiency and biological aging
Zhou, J., Fan, M., Lett, A. M., Jin, G., You, Q., Zeng, J., Chen, B., Wu, Y., Xing, H., & Xu, S. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf102 · Cited by 9
Effect of Vitamin E on Transcriptomic Alterations in Alzheimer’s Disease
Ekeuku, S. O., Murshid, N. M., Shukri, S. N., Sahardi, N. F. N. M., & Makpol, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512372 · Cited by 9
Signs of Alzheimer’s Disease: Tied to Aging
Chen, J., Zhu, Z., & Xu, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114974 · Cited by 12
Bennett, J. P. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.03.034 · Cited by 11
Wang, G., Mao, Z., Zhou, X. J., Zou, Y., & Zhao, M. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-662 · Cited by 8
Kostyunina, O. V., Komoltsev, I. G., Timokhova, A. V., Belikova, A., Balan, S. I., & Gulyaeva, N. V. (2024) · Neurochemical Journal · doi:10.1134/s1819712424700557 · Cited by 9
Zhang, J., Xie, D., Jiao, D., Zhou, S. Y., Liu, S., Ju, Z., Hu, L., Li, Q., Yao, C., & Chen, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32688 · Cited by 19
Renal aging and mitochondrial quality control
Guo, X., Wang, J., Wu, Y., Zhu, X., & Xu, L. (2024) · Biogerontology · doi:10.1007/s10522-023-10091-6 · Cited by 8
Kousi, M., Boix, C., Park, Y. P., Mathys, H., Sledzieski, S., Peng, Z., Bennett, D. A., Tsai, L.-H., & Kellis, M. (2022) · doi:10.1101/2022.04.21.489103 · Cited by 7
“However, these did not express all classical senescence markers (e.g. CDKN1A/2A), suggesting a possibly distinct neuronal and oligodendrocyte pre-apoptotic state 33 .”
BackgroundLes nouveaux traitements de la maladie d’Alzheimer
Delrieu, J., & Vellas, B. J. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.01.018 · Cited by 13
Senatore, E., Avolio, R., Rinaldi, L., Chiuso, F., Oliva, M. A., DˈAmbrosio, C., Bianco, A. G., Dalla, E., Pagnotta, S. M., Flammia, R., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00425-5 · Cited by 8
Mechanisms of Transsynaptic Degeneration in the Aging Brain
Wall, R. V., Basavarajappa, D. K., Klistorner, A. I., Graham, S. L., & You, Y. (2024) · Aging and Disease · doi:10.14336/ad.2024.03019 · Cited by 11
Magri, C., Vitali, E., Cocco, S., Giacopuzzi, E., Rinaudo, M., Martini, P. G. V., Barbon, A., Grassi, C., & Gennarelli, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147629 · Cited by 8
Luo, C., Nakagawa, M., Yoichi, S. U. M. I., Matsushima, Y., Uemura, M., Honda, Y., & Matsumoto, N. (2024) · Dental Materials Journal · doi:10.4012/dmj.2023-262 · Cited by 8
Carvalho, D. B., Díaz‐Amarilla, P., Dapueto, R., Santi, M. D., Duarte, P., Savio, E., Engler, H., Abin‐Carriquiry, J. A., & Arredondo, F. (2023) · Journal of Molecular Neuroscience · doi:10.1007/s12031-023-02105-2 · Cited by 8
The Azalea Hypothesis of Alzheimer Disease: A Functional Iron Deficiency Promotes Neurodegeneration
LeVine, S. M. (2023) · The Neuroscientist · doi:10.1177/10738584231191743 · Cited by 9
An Overview of Transgenic Mouse Models for the Study of Alzheimer’s Disease
Lopes, P. A., Pádua, M. S., & Guil‐Guerrero, J. L. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2010002 · Cited by 10
Exploring the causal relationship between telomere regulation, aging and neurological disorders
Gupta, G., Ali, H., Singh, S. K., Dua, K., & Jha, S. K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102930 · Cited by 9
Jones, E. J., Skinner, B. M., Parker, A., Baldwin, L., Greenman, J., Carding, S. R., & Funnell, S. G. P. (2024) · Biomicrofluidics · doi:10.1063/5.0200459 · Cited by 7
Ding, Y., Jiang, C., Chen, L., Liu, X., & Shao, B. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115135 · Cited by 6
Iacono, A., Oremus, M., Maxwell, C. J., & Tyas, S. L. (2023) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2023.2226855 · Cited by 9
Santa-Helena, E., Falco, A. D., Cukierman, D. S., Gioda, A., Gioda, C. R., & Rey, N. A. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202400356 · Cited by 5
p300 inhibition delays premature cellular senescence
Fede, E. D., Taci, E., Castiglioni, S., Rebellato, S., Ancona, S., Grazioli, P., Parodi, C., Colombo, E. A., Bernardelli, C., Lesma, E. A., et al. (2025) · npj Aging · doi:10.1038/s41514-025-00251-y · Cited by 8
Evolving insights into the identity and function of dark microglia
Flury, A., St-Pierre, M.-K., Ayata, P., & Tremblay, M.-È. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2025.11.002 · Cited by 8
Evaluating senescence-targeted approaches in Alzheimer’s Disease: What we know and what lies ahead
Doshi, P. P., Desale, S. H., Khutale, A. A., Sabarathinam, S., & Suresh, S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103029 · Cited by 8
Astragaloside IV confronts amyloid-beta-induced astrocyte senescence via hsp90aa1
Xia, Y., Zeng, R., & Cao, Y. (2024) · Journal of Applied Biomedicine · doi:10.32725/jab.2024.015 · Cited by 6
Immunosenescence and Alzheimer’s Disease
Fülöp, T., Larbi, A., Khalil, A., Plotka, A., Laurent, B., Ramassamy, C., Bosco, N., Hirokawa, K., Frost, E. H., & Witkowski, J. M. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-87532-9_9 · Cited by 5
Yang, J., Yin, N., Yang, R., & Faiola, F. (2024) · Reviews of Environmental Contamination and Toxicology · doi:10.1007/s44169-024-00059-z · Cited by 9
Frost, J., Schmitzer, B., Töpperwien, M., Eckermann, M., Franz, J., Stadelmann, C., & Salditt, T. (2022) · doi:10.1101/2022.10.07.22280811 · Cited by 5
Recent advances in nanotechnology and its application for neuro-disease: a review
Radhakrishnan, K. G., Kumar, P. S., Rangasamy, G., Ankitha, K., Niyathi, V., Manivasagan, V., & Saranya, K. (2023) · Applied Nanoscience · doi:10.1007/s13204-023-02958-4 · Cited by 6
MicroRNA profiles in plasma-derived extracellular vesicles across the human lifespan
Ráez-Meseguer, C., Navas-Enamorado, C., Capó, X., Galmes-Panades, A. M., de la Llave, A. M., Mendez-Varela, M., Martinez-Calvo, M., Bennasar-Arbos, A., Sánchez-Polo, A., Masmiquel, L., et al. (2026) · npj Aging · doi:10.1038/s41514-025-00321-1 · Cited by 11
Zhao, C., Zhao, L., Liu, Y., Sun, L.-Q., Li, X., Wang, Y., & Sun, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1569798 · Cited by 10
Sustaining Brain Youth by Neural Stem Cells: Physiological and Therapeutic Perspectives
dos Santos, M. A., Moreira, J. A. F., Santos, S. S., & Solá, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04774-z · Cited by 8
Advancements in research on the anti-aging effects and mechanisms of flavonoids in natural products
Li, W., Zhang, L., Xie, X., Shi, X.-F., & Ma, Q. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1637992 · Cited by 5
Wang, X., Hu, J., Xie, S., Li, W., Zhang, H., Huang, L., Qian, Z., Zhao, C., & Hu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113024 · Cited by 6
Cognitive impairment and risk of dementia in heart failure: the exuberating role of digoxin
Al-Kuraishy, H. M., Fahad, E. H., Sulaiman, G. M., Mohammed, H. A., Jabir, M. S., Al-Gareeb, A. I., & Albuhadily, A. K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04457-5 · Cited by 6
de Rezende, V. L., da Costa, M. D. A., Martins, C. D., Mathias, K., Gonçalves, C. L., Barichello, T., & Petronilho, F. C. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04361-7 · Cited by 7
Respostas cardiovasculares agudas frente a diferentes testes funcionais em idosos
de Morais, K. A., Pereira, M. D. G. G., da Cruz, C. J. G., & Drummond, A. (2019) · Revista Kairós Gerontologia · doi:10.23925/2176-901x.2019v22i1p109-122 · Cited by 2
Research progress of cell senescence in Alzheimer's disease: mechanisms and therapy
Cai, J., Yang, L. C., Xu, Y., Wang, L., Zhang, M., Qiao, J., Qian, X., Zhu, H., & Cai, M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177697 · Cited by 6
Sasaki, K., & Isoda, H. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105021 · Cited by 5
Accelerated neuronal aging in vitro ∼melting watch ∼
Inagaki, E., Yoshimatsu, S., & Okano, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.868770 · Cited by 4
Ratushnyak, M. G., Semochkina, Y. P., Zhirnik, A. S., & Смирнова, О. Д. (2021) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-021-05368-0 · Cited by 320
Sweeney, E. M., Abate, G., Bakker, B. R. V., Mastinu, A., Lai, Y., Uberti, D. L., Nilsson, P., & Tambaro, S. (2026) · Aging Cell · doi:10.1111/acel.70478 · Cited by 8
Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach
Atkinson, J., Dokiburra, A., Groover, H., Godbout, J. P., Segal, B. M., & Zhang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1681724 · Cited by 7
Wang, Y. S., Liu, Q., Wu, J., Meng, K., Zhou, L., & Ye, F. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1598608 · Cited by 9
Proteomic characteristics of plasma and blood cells in natural aging rhesus monkeys
Wu, N., Xiao, F., Zhang, J., Chi, Y., Zhai, Y., Chen, B., & Lu, J. (2022) · PROTEOMICS · doi:10.1002/pmic.202200049 · Cited by 6
Chu, J., Hu, H., Xu, W., Lu, X., Zhou, H., Hao, M., Wang, L., Li, S., Ji, W., Li, G., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102157 · Cited by 8
Borowik, A., Lawrence, M. M., Peelor, F. F., Piekarz, K. M., Crosswhite, A., Richardson, A. G., Miller, B. F., Remmen, H. V., & Brown, J. L. (2024) · GeroScience · doi:10.1007/s11357-024-01070-x · Cited by 4
Metadata
- Authors
- Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Laboratory of Histology & Embryology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Goudi, 115-27 Athens, Greece
- Corresponding author
- Gorgoulis, Vassilis G.
- Papadopoulos, Dimitrios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-09-27
- Volume
- 19
- Issue
- 10
- Pages
- 2937
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6213570
- OpenAlex
- W2892390537
- Cited by
- 448
- References
- 385
- Citations by year
- 2026: 46 · 2025: 63 · 2024: 90 · 2023: 63 · 2022: 57 · 2021: 58 · 2020: 47 · 2019: 23 · 2018: 1
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Multiple Sclerosis Society (207495)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cellular senescence, aging, neurodegenerative diseases, senescence markers, lipofuscin, neurons, glial cells, Alzheimer's disease, Parkinson's disease, multiple sclerosis, senolytics, age-related diseases
- MeSH terms
- Aging, Animals, Humans, Cellular Senescence, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.